May 6, 2015
Medicalresearch.com interview with Dr. Matthias Eiber, corresponding author of a recent study reported in The Journal of Nuclear Medicine:
What is the background for this study? What are the main findings?
Dr. Eiber: The background of the study is the investigation of a novel 68Ga-PSMA ligand using PET/CT in the workup of patients with recurrent prostate cancer after radical prostatectomy. Hereby, we found substantial higher detection rate compared to other methods. In total 222 (89.5%) patients showed pathological findings in 68Ga-PSMA-ligand PET/CT. Stratified by PSA-level the detection rates were 96.8%,93.0%,72.7% and 57.9% of ≥2,1-<2, 0.5-<1 and 0.2-<0.5ng/mL, respectively.
What should clinicians and patients take away from your report?
Dr. Eiber: For clinicians and patients the main point includes that 68Ga-PSMA PET/CT enables detection and localization of recurrent prostate cancer at a higher efficiency than reported for other tracers/imaging modalities. Most importantly, it reveals a high number of positive findings in the clinically important range of low PSA-values (<0.5ng/mL), which in many cases can substantially influence the further clinical management.